Lori Minasian

Lori Minasian has overseen the National Cancer Institute portfolio of multi-cancer early detection trials, ensuring rigorous evaluation of MCED technologies through large-scale randomized controlled studies designed to demonstrate mortality benefit. Her work on balancing screening benefits against potential harms including overdiagnosis and false positives has shaped FDA regulatory requirements for MCED tests. Her leadership in coordinating multi-institutional screening trials has established the infrastructure necessary for evaluating blood-based cancer detection at population scale.